Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Belsomra Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG064

    Belsomra (suvorexant)

    Customize your policy alerts

    Sign up for Oscar Health Policy PG064 alerts

    Get alerted when Policy PG064 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Oscar Health prior authorization for Belsomra (suvorexant) in adults with insomnia characterized by difficulty with sleep onset and/or sleep maintenance, including initial authorization, reauthorization, documentation, duration, and coverage limitations.

    Policy Summary
    PayerOscar Health
    PolicyBelsomra (suvorexant)
    Policy CodePolicy PG064
    Change TypeNo material change
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document qualifying insomnia, behavioral therapy, and failure or inability to use at least three alternative therapies for one month.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum age
    3Alternative therapies required
    1 monthTrial duration per therapy
    12 monthsInitial authorization
    12 monthsReauthorization
    InsomniaCovered indication

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following initial authorization criteria are met:

    ALL of the following

    • The member is 18 years of age or older.
    • The member has a diagnosis of insomnia characterized by difficulty with sleep onset and/or sleep maintenance.
    • Clinical assessment is provided showing that the member has been assessed for concurrent conditions (e.g., anxiety, chronic pain, overactive thyroid) and/or precipitating factors (e.g., certain medicines, caffeine) that are contributing to the insomnia.
    • The member has had a trial of psychological and/or behavioral therapy, such as cognitive behavioral therapy for insomnia (CBT-i), stimulus control, psychoeducation/sleep hygiene interventions, sleep-restriction therapy, or relaxation training.
    Policy Summary
    PayerOscar Health
    PolicyBelsomra (suvorexant)
    Policy CodePolicy PG064
    Change TypeNo material change
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document qualifying insomnia, behavioral therapy, and failure or inability to use at least three alternative therapies for one month.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundBehavioral Therapy DefinitionsInitial TherapyReauthorizationRequired Previous TherapiesAuthorization Duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    The member is unable to use or has tried and failed a minimum ONE (1) month trial of at least THREE of the following therapies:

    • AT LEAST THREE

      • Doxepin.
      • Doxylamine succinate.
      • Eszopiclone.
      • Ramelteon.
      • Zaleplon.
      • Zolpidem tartrate.
  1. Clinical chart documentation is provided for review to substantiate the above listed requirements.

    If all prior authorization criteria are met, Belsomra (suvorexant) will be approved for up to 12 months.

  2. Continuation Therapy

    Reauthorization for up to 12 months will be granted if BOTH of the following continuation criteria are met:

    ALL of the following

    • The member still meets the applicable initial criteria.
      • ONE of the following

        • Clinical improvement (e.g., decreasing sleep latency) in symptoms since starting the requested medication.
        • Disease stability (e.g., improving sleep maintenance) since starting the requested medication.

    Coverage is limited to Belsomra (suvorexant) for insomnia characterized by difficulty with sleep onset and/or sleep maintenance.

    Belsomra (suvorexant) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Belsomra (suvorexant). Initial authorization requires fulfillment of all applicable medical-necessity criteria before the medication can be approved for up to 12 months.

    • Member is 18 years of age or older.
    • Member has insomnia characterized by difficulty with sleep onset and/or sleep maintenance.
    • Clinical assessment addresses concurrent conditions and/or precipitating factors contributing to insomnia.
    • Member has tried psychological and/or behavioral therapy.
    • Member is unable to use or has tried and failed at least three qualifying alternative therapies, with a minimum one-month trial for each applicable therapy.
    • Clinical chart documentation substantiates all requirements.
    Prior Authorization

    Reauthorization Requirements

    Reauthorization for up to 12 months requires that the member continue to meet the applicable initial criteria and that recent documentation demonstrates a therapeutic response to Belsomra.

    • Documentation must be from within the last 12 months.
    • Therapeutic response must include either clinical improvement, such as decreasing sleep latency, or disease stability, such as improving sleep maintenance, since starting Belsomra.
    Step Therapy

    Behavioral Therapy and Alternative Drug Trials

    Before initial authorization, the member must have tried psychological and/or behavioral therapy and must be unable to use or have tried and failed at least three listed alternative therapies. Each alternative therapy trial must be for a minimum of one month unless the member is unable to use it.

    • Psychological or behavioral therapy may include cognitive behavioral therapy for insomnia (CBT-i), stimulus control, psychoeducation or sleep hygiene interventions, sleep-restriction therapy, and relaxation training.
    • Qualifying alternatives include doxepin, doxylamine succinate, eszopiclone, ramelteon, zaleplon, and zolpidem tartrate.
    • At least three of the listed alternative therapies are required.
    Documentation Required

    Initial Authorization Documentation

    Submit clinical chart documentation supporting the initial request and demonstrating that all medical-necessity requirements are satisfied.

    • Document that the member is at least 18 years old.
    • Document the diagnosis of insomnia, including difficulty with sleep onset and/or sleep maintenance.
    • Document assessment for contributing concurrent conditions, such as anxiety, chronic pain, or overactive thyroid, and precipitating factors, such as certain medicines or caffeine.
    • Document the required psychological or behavioral therapy and qualifying alternative-therapy trials.
    • Provide documentation for review substantiating the listed requirements.
    Documentation Required

    Therapeutic Response Documentation

    For reauthorization, submit recent chart documentation from within the last 12 months showing that the member has experienced a therapeutic response to Belsomra.

    • Document clinical improvement in symptoms since starting Belsomra, such as decreasing sleep latency; or
    • Document disease stability since starting Belsomra, such as improving sleep maintenance.
    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied when the member does not meet the required medical-necessity criteria or when supporting documentation is incomplete.

    • Member is younger than 18 years of age.
    • Insomnia diagnosis or qualifying sleep-onset or sleep-maintenance difficulty is not documented.
    • Concurrent conditions and/or precipitating factors contributing to insomnia have not been assessed or documented.
    • Required psychological or behavioral therapy has not been tried or documented.
    • The member has not tried and failed, or is not unable to use, at least three qualifying alternative therapies with the required minimum one-month trials.
    • Clinical chart documentation does not substantiate the initial requirements.
    Denial Risk

    Uncovered Indication

    Belsomra for any indication other than insomnia characterized by difficulty with sleep onset and/or sleep maintenance is considered not medically necessary by the Plan and may be denied as experimental, investigational, or unproven.

    • Use must be for the covered insomnia indication described in the initial authorization criteria.
    • Requests for other indications are not medically necessary under this policy.
    Denial Risk

    Reauthorization Criteria Not Met

    Reauthorization may be denied when the member no longer meets the applicable initial criteria or when the required recent therapeutic-response documentation is not provided.

    • The member does not continue to meet the initial authorization criteria.
    • Documentation is not recent, meaning it is not from within the last 12 months.
    • The record does not show clinical improvement or disease stability since starting Belsomra.
    • The request lacks sufficient chart documentation to substantiate continued medical necessity.

    Policy Background

    Belsomra (suvorexant) is an orexin receptor antagonist approved in 2014 for insomnia involving difficulty with sleep onset and/or sleep maintenance. Chronic insomnia may be treated with both pharmacologic and non-pharmacologic therapies.

    Behavioral Therapy Definitions

    Cognitive behavioral therapy for insomnia
    DefinitionA non-pharmacologic therapy focused on thoughts and behavior.
    FocusAddresses thoughts and behavior related to sleep.
    PurposeImproves sleep.
    Stimulus control
    DefinitionA behavioral method used in insomnia care.
    GoalRemoves the negative association between the bed and trouble sleeping.
    Sleep-related purposeHelps address trouble sleeping by changing the association with the bed.
    Relaxation training
    DefinitionA method for lowering arousal states and improving sleep.
    MethodsMay involve muscle relaxation, controlled breathing, and guided imagery.
    Sleep-related purposeLowers arousal states to improve sleep.

    Initial Therapy

    Initial Therapy Criteria

    Belsomra is medically necessary when ALL initial authorization criteria are met.

    Initial Belsomra authorization

    • Eligibility and clinical requirements

      • The member is 18 years of age or older.Age ≥ 18 years
      • The member has a diagnosis of insomnia characterized by difficulty with sleep onset and/or sleep maintenance.
      • Clinical assessment is provided showing that the member has been assessed for concurrent conditions and/or precipitating factors contributing to the insomnia.

        Examples include anxiety, chronic pain, overactive thyroid, certain medicines, and caffeine.

      • The member has had a trial of psychological and/or behavioral therapy.

        Examples include cognitive behavioral therapy for insomnia, stimulus control, psychoeducation or sleep hygiene interventions, sleep-restriction therapy, and relaxation training.

    • Alternative therapy requirement

      • Doxepin
      • Doxylamine succinate
      • Eszopiclone
      • Ramelteon
      • Zaleplon
      • Zolpidem tartrate
    • Documentation: Clinical chart documentation is provided for review to substantiate the above listed requirements.

    Reauthorization

    Reauthorization Criteria

    Reauthorization for up to 12 months will be granted if BOTH of the following are met.

    Belsomra reauthorization

    • Initial criteria remain met: The member still meets the applicable initial criteria.
    • Therapeutic response

      • Clinical improvement in symptoms since starting Belsomra.

        Example: decreasing sleep latency.

      • Disease stability since starting Belsomra.

        Example: improving sleep maintenance.

    Required Previous Therapies

    StepRequired therapyRequirement
    1Psychological and/or behavioral therapyA trial is required; examples include cognitive behavioral therapy for insomnia, stimulus control, psychoeducation/sleep hygiene interventions, sleep-restriction therapy, and relaxation training.
    2At least 3 of the following 6 alternative therapies: doxepin; doxylamine succinate; eszopiclone; ramelteon; zaleplon; or zolpidem tartrateThe member must be unable to use or have tried and failed a minimum 1-month trial of each required therapy.

    Authorization Duration

    Initial authorization
    MedicationBelsomra (suvorexant)
    Authorization typeInitial authorization
    Approval durationUp to 12 months
    Reauthorization
    MedicationBelsomra (suvorexant)
    Authorization typeReauthorization
    Authorization durationUp to 12 months